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ABSTRACT: A structure-guided design strategy was used to
improve the resistance profile of HIV-1 protease inhibitors by
optimizing hydrogen bonding and van der Waals interactions
with the protease while staying within the substrate envelope.
Stereoisomers of 4-(1-hydroxyethyl)benzene and 4-(1,2-
dihydroxyethyl)benzene moieties were explored as P2′ ligands
providing pairs of diastereoisomers epimeric at P2′, which
exhibited distinct potency profiles depending on the config-
uration of the hydroxyl group and size of the P1′ group. While
compounds with the 4-(1-hydroxyethyl)benzene P2′ moiety
maintained excellent antiviral potency against a panel of
multidrug-resistant HIV-1 strains, analogues with the polar 4-
(1,2-dihydroxyethyl)benzene moiety were less potent, and only
the (R)-epimer incorporating a larger 2-ethylbutyl P1′ group showed improved potency. Crystal structures of protease−
inhibitor complexes revealed strong hydrogen bonding interactions of both (R)- and (S)-stereoisomers of the hydroxyethyl
group with Asp30′. Notably, the (R)-dihydroxyethyl group was involved in a unique pattern of direct hydrogen bonding
interactions with the backbone amides of Asp29′ and Asp30′. The SAR data and analysis of crystal structures provide insights
for optimizing these promising HIV-1 protease inhibitors.
■ INTRODUCTION
The HIV-1 protease is a major target for developing antiviral
therapies against HIV-1. Drug discovery efforts, aided by
structure-based drug design, have led to the development of
nine FDA-approved HIV-1 protease inhibitors (PIs).1 All
approved HIV-1 PIs are competitive inhibitors, and most
contain different dipeptide isosteres as transition state
mimetics.2 In addition to extensive hydrophobic interactions,
PIs mainly rely on a number of direct and water-mediated
hydrogen bonds with the protease for potency. The clinical
efficacy of HIV-1 PIs has significantly improved since this drug
class was first introduced in the mid-1990s. The development
of second-generation PIs with improved potency, tolerability,
and pharmacokinetic profiles and the introduction of low-dose
ritonavir as a pharmacokinetic booster in PI-based antire-
troviral therapy (ART) have led to improved clinical outcomes.
Moreover, PIs allow an exceedingly high level of viral
inhibition at clinical concentrations due to cooperative
dose−response curves with high slopes.3,4 These transition-
state mimetic inhibitors represent the most potent anti-HIV-1
drugs.
Despite much success, PI-based therapies are associated with
drawbacks that limit their effectiveness, including major side
effects, unfavorable pharmacokinetics, and the acquisition of
many viable multidrug-resistant (MDR) protease variants.5,6
Drug resistance remains a major issue, as the prevalence of PI
resistance mutations increases with duration of ART and is
much higher among PI-experienced patients.7,8 Even the most
effective PI-based regimens have been reported to select
multiple resistance mutations in the protease, resulting in
reduced virologic response.7−10 Moreover, the prevalence of
transmitted drug resistance continues to increase, which is an
added challenge in the treatment of HIV infections.11,12 The
emergence of MDR protease variants presents a challenge to
structure-based drug design (SBDD), as the target is not a
single protein but an ensemble of closely related proteases. The
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new PIs must maintain activity not only against existing MDR
protease variants but also against future variants that may
emerge. These challenges require developing new SBDD
strategies to optimize PI potency while avoiding resistance.
The design strategy to maximize interactions in the HIV-1
protease active site, particularly with the protein backbone
atoms, has been quite successful, leading to the development of
the FDA-approved drug darunavir.13,14 Darunavir (DRV, 1) is
a highly potent inhibitor of HIV-1 protease with a low pM
inhibition constant (Ki) and a high genetic barrier to
resistance. The key structural feature that distinguishes DRV
from previous generation HIV-1 PIs is the bis-tetrahydrofuran
(bis-THF) moiety at the P2 position (Figure 1) that makes
strong hydrogen bonding interactions with the backbone NH
of Asp29 and Asp30 in the protease active site.1,13,15 The
application of the design strategy to maximize interactions with
the backbone atoms of HIV-1 protease has recently led to the
discovery of DRV analogues that maintain exceptional potency
against MDR HIV-1 variants including DRV-resistant
strains.16−19
Among the strategies proposed to rationally design PIs
against drug-resistant HIV-1 variants, the substrate envelope
model provides a more comprehensive framework to
incorporate drug resistance considerations into SBDD.20−22
This structure-guided design strategy aims to optimize
hydrogen bonding and van der Waals (vdW) interactions
with the protease to improve potency against MDR protease
variants, while constraining inhibitors within the substrate
envelope to avoid resistance.23 We previously used the
substrate envelope-guided design strategy to develop a series
of highly potent DRV analogues that maintained excellent
antiviral potencies against a panel of clinically relevant MDR
HIV-1 strains.23 The X-ray cocrystal structures confirmed that
the designed PIs optimally fill the substrate envelope and make
enhanced vdW contacts and hydrogen bonding interactions
with HIV-1 protease.23,24
Among these PIs, compounds 3 and 4 (Figure 1) with the 4-
(hydroxymethyl)benzene P2′ moiety were identified as
promising lead compounds due to distinct polar interactions
of the benzylic hydroxyl group with the protease. Cocrystal
structures of PIs 3 and 4 bound to wild-type HIV-1 protease
revealed that the P2′ benzylic hydroxyl group is positioned
close to the backbone NH of Asp29′ and Asp30′ in the S2′
subsite. The hydroxyl group makes a direct hydrogen bond
only with the backbone NH of Asp30′, which is slightly closer
than the NH of Asp29′ (Figure S1).23,24 We reasoned that
introduction of a small hydrophobic group such as a methyl at
the benzylic position could shift the resulting secondary
hydroxyl group closer to the backbone NH of Asp29′, allowing
polar interactions with both residues, as well as additional vdW
contacts in the S2′ subsite. Similarly, a hydroxymethyl group at
the benzylic position could serve the same purpose, with the
primary hydroxyl group making additional polar interactions in
the S2′ subsite of HIV-1 protease (Figure 1). Optimal polar
interactions of the P2′ moiety with the backbone NH of
Asp29′ and Asp30′ could potentially mimic the strong
hydrogen bonding interaction of the P2 bis-THF moiety,
further improving potency against MDR HIV-1 variants.
Previous efforts to identify an optimal P2′ moiety have only
been partially successful, and none of the reported P2′ moieties
make direct hydrogen bonding interactions with the backbone
atoms of both Asp29′ and Asp30′.16,25−27
On the basis of insights from the structural analysis and
modeling, modifications of the P2′ moiety of PIs 3 and 4, in
combination with variations at the P1′ group, were explored to
enhance inhibitor interactions in the S1′ and S2′ subsites.
Here, we describe the substrate envelope-guided design,
synthesis, evaluation of biochemical and antiviral potency,
and crystal structure analysis of a series of novel HIV-1 PIs.
The inhibitors were designed by incorporating stereoisomers
of the 4-(1-hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)-
benzene moieties as novel P2′ ligands to enhance hydrogen
bonding interactions in the S2′ subsite of HIV-1 protease.
Structure−activity relationship (SAR) studies identified a
number of compounds with improved potency profiles
compared to DRV and the parent compounds against highly
drug-resistant HIV-1 strains representing the spectrum of
clinically relevant MDR viruses. We also report high-resolution
crystal structures of all new compounds bound to wild-type
HIV-1 protease revealing key interactions of the chiral 4-(1-
hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene
moieties in the protease active site. A unique pattern of
hydrogen bonding interactions was observed for compounds
incorporating the (R)-4-(1,2-dihydroxyethyl)benzene as P2′
ligand, where both P2 and P2′ moieties make direct hydrogen
bonds with the backbone NH of residues Asp29/29′ and
Asp30/30′.
■ CHEMISTRY
The synthesis of HIV-1 PIs with the (S)- and (R)-(1-
hydroxyethyl)benzene moieties at the P2′ position is outlined
Figure 1. Structures of HIV protease inhibitors DRV (1), P2′ 4-(1-
hydroxymethyl)benzene analogues (2−4), and designed compounds
with stereochemically defined P2′ 4-(1-hydroxyethyl)benzene and
(12−17) and 4-(1,2-dihydroxyethyl)benzene (22−27) moieties. The
canonical nomenclature for the inhibitor moiety position is indicated
using DRV.
in Scheme 1. We envisioned generating both stereoisomers of
the hydroxyethyl group at the P2′ moiety from the
corresponding 4-acetylbenzene derivatives by enantioselective
reduction of the acetyl group using the Corey−Bakshi−Shibata
(CBS) catalyst.28 The 4-acetylbenzenesulfonamide intermedi-
ates 8a−c were prepared from the commercially available
epoxide 5 in two steps. Ring opening of the chiral epoxide 5
with selected amines provided the amino alcohols 6a−c, which
were reacted with 4-acetylbenzenesulfonyl chloride 7 using
Na2CO3 as a base under biphasic conditions to afford the 4-
acetylbenzenesulfonamide intermediates 8a−c in excellent
yield. Reduction of the acetyl group using BH3-THF in the
presence of the chiral catalyst (R)-CBS-Me provided the
required intermediates with the (S)-(1-hydroxyethyl)benzene
moiety 9a−c with excellent enantioselectivity. After purifica-
tion by flash chromatography, the products were recrystallized
from a mixture of EtOAc and hexanes to ensure chiral purity.
Removal of the Boc protecting group with TFA and reaction of
the resulting amine salts with the bis-THF activated carbonate
11 provided the target compounds 12, 14, and 16 with the
(S)-4-(1-hydroxyethyl)benzene moiety at the P2′ position.
Inhibitors with the corresponding (R)-4-(1-hydroxyethyl)-
benzene at the P2′ position were prepared similarly using
the (S)-CBS-Me as the catalyst during the stereoselective
reduction step and provided the desired inhibitors 13, 15, and
17.
The protease inhibitors with the (R)- and (S)-4-(1,2-
dihydroxyethyl)benzene moieties at the P2′ position were
prepared from the corresponding styrene derivatives by
Sharpless asymmetric dihydroxylation using the AD-mix
catalyst29,30 as outlined in Scheme 2. Briefly, reactions of
amino alcohols 6a−c with 4-vinylbenzenesulfonyl chloride 18
using Na2CO3 as a base under biphasic conditions provided
the 4-vinylbenzenesulfonamide intermediates 19a−c. The
asymmetric dihydroxylation reaction using AD-mix-β as a
chiral catalyst proceeded smoothly and provided the required
intermediates with the (R)-4-(1,2-dihydroxyethyl)benzene
moiety 20a−c. In all cases the (S)-epimer was not detected
by 1H NMR; however, the products were recrystallized to
provide enantiomerically pure intermediates 20a−c. Analogous
to the compound series with the 4-(1-hydroxyethyl)benzene
P2′ moiety, Boc deprotection and the reaction of the resulting
amine salts with the bis-THF carbonate 11 provided the target
compounds 22 , 24 , and 26 with the (R)-4-(1,2-
dihydroxyethyl)benzene moiety at the P2′ position. Inhibitors
with the corresponding (S)-4-(1,2-dihydroxyethyl)benzene
moiety at the P2′ position were prepared in a similar fashion
using the AD-mix-α as the chiral catalyst in the asymmetric
dihydroxylation reaction and provided the target inhibitors 23,
25, and 27.
■ RESULTS AND DISCUSSION
Our goal was to improve the potency of PIs against MDR HIV-
1 variants by optimizing hydrogen bonding interactions in the
S2′ subsite of HIV-1 protease. Specifically, we explored the
possibility of additional hydrogen bonding interactions
between the hydroxyl group of the P2′ moiety and the
backbone amide NH of Asp29′ and Asp30′ on the basis of an
analysis of 3- and 4-bound HIV-1 protease structures and
molecular modeling. Addition of a methyl group to the
hydroxymethyl substituent was expected to shift the hydroxyl
group closer to the backbone NH of Asp29′, while increasing
vdW interactions with residues in the S2′ subsite. Similarly,
replacement of the hydroxymethyl group with a more polar
1,2-dihydroxyethyl was intended to enhance polar interactions;
particularly the second hydroxyl group was expected to replace
the water-mediated interactions between the P2′ moiety and
the Asp30′ side chain. However, due to the free rotation of the
hydroxyethyl and dihydroxyethyl groups, modeling did not
provide a clear distinction which of the two stereoisomers
would provide optimal polar and vdW interactions. Thus, both
(R)- and (S)-stereoisomers of 4-(1-hydroxyethyl)benzene and
Scheme 1. Synthesis of Protease Inhibitors Incorporating
(S)- and (R)-4-(1-Hydroxyethyl)benzene as P2′ Ligandsa
aReagents and conditions: (a) RNH2, EtOH, 70 °C, 3 h, 79−91%;
(b) Na2CO3, EtOAc, H2O, RT, 18 h, 98−100%; (c) R-CBS-Me, BH3-
THF (1 M), THF, 0 °C to RT, 3 h, 57−85%; (d) TFA, CH2Cl2, RT,
1 h; (e) DIEA, CH3CN, RT, 24 h, 73−91%; (f) S-CBS-Me, BH3-THF
(1 M), THF, 0 °C to RT, 3 h, 47−87%.
4-(1,2-dihydroxyethyl)benzene moieties were explored as P2′
ligands in combination with three P1′ groups of varying size
and hydrophobicity.
Enzyme Inhibition Assays. The binding affinity of HIV-1
PIs has reached a level where assessing the inhibition of wild-
type protease using standard FRET-based assays is quite
difficult. Accurate measurement of inhibition constants in the
low pM range remains a challenge even with the recently
reported highly sensitive fluorogenic assay.31 Due to these
limitations, two drug-resistant protease variants, I84V and
I50V/A71V, were selected to assess the potency of new PIs.
I84V is a common drug resistance mutation that reduces
susceptibility to all FDA-approved PIs, while I50V/A71V
mutations arise in response to therapy with APV- and DRV-
based regimens, resulting in reduced susceptibility to these PIs.
The enzyme inhibition constants (Ki) were determined against
the I84V and I50V/A71V protease variants using the highly
sensitive FRET assay;31 DRV was used as a control in all assays
(Table 1).
DRV retained excellent potency against the I84V and I50V/
A71V protease variants (Ki = 25 pM and 75 pM, respectively)
compared to that reported for wild-type protease (Ki = 5−16
pM).13,23,31 Compound 3, which incorporates a 4-
(hydroxymethyl)benzene moiety as P2′ ligand and (S)-2-
methylbutyl group at the P1′ position, showed better potency
against the I84V protease but was equipotent to DRV against
the I50V/A71V variant. Analogue 4, with a larger 2-ethylbutyl
group at the P1′ position, was more active than DRV against
both the I84V and I50V/A71V protease variants. The
corresponding analogue 2 with the isobutyl P1′ group was
previously reported to be equipotent to DRV against wild-type
protease but exhibited relatively lower antiviral potency,
presumably due to reduced hydrophobicity.13,32 Thus, as we
have previously shown, PIs with 4-(hydroxymethyl)benzene as
the P2′ moiety in combination with larger, more hydrophobic
(S)-2-methylbutyl and 2-ethylbutyl P1′ groups maintained
potency against drug-resistant protease variants.
Replacement of the 4-(hydroxymethyl)benzene P2′ moiety
of PIs 2−4 with (S)- and (R)-4-(1-hydroxyethyl)benzene
resulted in pairs of diastereoisomers epimeric at P2′. The P2′
hydroxyethyl analogues 12−17 showed excellent inhibitory
potencies against the I84V and I50V/A71V protease variants
with Ki values ranging between 20 and 132 pM. In each case,
both diastereoisomers were relatively less potent than the
corresponding parent hydroxymethyl compound, particularly
against the I84V protease variant. However, no major
difference in inhibitory potency was observed between P2′
epimeric compounds. Only compounds with the isobutyl P1′
group showed minor differences in inhibitory potencies
between the P2′ epimers, as diastereoisomer 12, with (S)-
configuration of the hydroxyethyl group, was slightly more
potent than the corresponding (R)-epimer 13. While this work
was underway, Ghosh et al. reported the synthesis of PIs 12
and 13 using a much longer reaction sequence; both
compounds were tested against wild-type HIV-1 protease,
and only compound 13 was evaluated for antiviral activity.33
Diastereoisomers 14 and 15, with the (S)-2-methylbutyl P1′
group, showed similar potencies against the I84V and I50V/
A71V protease variants, and both were less potent than the
parent 3. Similarly, no difference in inhibitory potency was
observed between diastereoisomers 16 and 17 incorporating
the 2-ethylbutyl P1′ group. However, analogues 16 and 17
were more potent against the I84V protease (Ki = 20 and 28
pM, respectively) and exhibited overall potency profiles
comparable to that of DRV. Together, these data demonstrate
that minor modifications to the P1′ and P2′ moieties result in
distinct potency profiles.
In contrast to the 4-(1-hydroxyethyl)benzene P2′ series,
compounds with the 4-(1,2-dihydroxyethyl)benzene P2′
moiety showed clear differences in inhibitory potency between
the P2′-epimers. Compounds incorporating the (R)-4-(1,2-
dihydroxyethyl)benzene P2′ moiety were 2−3-fold more
potent than the corresponding (S)-epimers. Diastereoisomer
Scheme 2. Synthesis of Protease Inhibitors Incorporating
(S)- and (R)-4-(1,2-Dihydroxyethyl)benzene as P2′
Ligandsa
aReagents and conditions: (a) Na2CO3, EtOAc, H2O, RT, 18 h, 75−
94%; (b) AD-mix-β, t-BuOH, H2O, RT, 4 h, 68−87%; (c) TFA,
CH2Cl2, RT, 1 h; (d) DIEA, CH3CN, RT, 24 h, 33−79%; (e) AD-
mix-α, t-BuOH, H2O, RT, 4 h, 47−86%.
22, with the isobutyl group at the P1′ position and (R)-
configuration of the dihydroxyethyl group, exhibited excellent
inhibitory potency against the I84V and I50V/A71V proteases,
while the corresponding (S)-epimer 23 was about 3-fold less
active against the I84V protease. A similar trend was observed
for diastereoisomers 24 and 25 incorporating the (S)-2-
methylbutyl P1′ group, though both compounds were 2-fold
less active against the I84V protease than the corresponding
isobutyl P1′ analogues 23 and 24. The analogue 26
incorporating the larger 2-ethylbutyl P1′ group and (R)-
configuration of the dihydroxyethyl group was the most potent
in this series, with enzyme potency against the I50V/A71V
protease variant comparable to that of DRV. Again, the
corresponding P2′ (S)-epimer 27 was 2−3-fold less potent
against the protease variants tested. Thus, the shape of the
hydrophobic group at P1′ and the configuration of the
dihydroxyethyl group at P2′ affected inhibitor potency against
drug-resistant protease variants.
Antiviral Assays. The potency and resistance profiles of
PIs were evaluated using a cell-based antiviral assay against
wild-type HIV-1 and three representative MDR variants
selected from a panel of clinically relevant multi-PI resistant
recombinant clones (Table 2, Table S1).34 Relative to the wild-
type HIV-1 strain NL4-3 (with a near consensus protease
sequence), the MDR variants contain 19, 20, and 24 amino
acid substitutions in the protease and are named SLK19,
VSL20, and KY24, respectively. All three variants show high-
level resistance and cross-resistance to multiple PIs including
DRV, as determined by the Monogram Biosciences (South San
Francisco, CA) PhenoSense assay.34 Accordingly, in antiviral
assays, the MDR variants exhibited increasingly high-level
resistance to DRV: compared to wild-type HIV-1, DRV was 6-
fold less potent against SLK19, 58-fold less potent against
VSL20, and 210-fold less potent against KY24. Thus, the three
selected MDR HIV-1 strains represent clinically relevant MDR
viruses with a wide spectrum of DRV resistance.
The 4-(hydroxymethyl)benzene P2′ analogues 3 and 4 were
equipotent to DRV against wild-type HIV-1 with EC50 values
Table 1. Protease Inhibitory Activity of PIs 12−17 and 22−
27 against Drug-Resistant Variantsa
aNT: not tested.
Table 2. Antiviral Potency of PIs 12−17 and 22−27 against
WT HIV-1 and Drug-Resistant Variantsa
Antiviral EC50 (nM) (fold change)
c
Inhibitor cLogPb WT SLK19 VSL20 KY24
12 2.885 4.7 31 (7) 117 (25) 352 (75)
13 2.885 7.5 100 (13) 148 (20) 360 (48)
14 3.414 4.6 49 (11) 281 (61) 490 (107)
15 3.414 4.2 91 (22) 291 (69) 342 (81)
16 3.943 4.4 26 (6) 112 (25) 196 (45)
17 3.943 5.1 32 (6) 420 (82) 345 (68)
22 1.673 176 NT NT NT
23 1.673 189 NT NT NT
24 2.202 80 NT NT NT
25 2.202 92 NT NT NT
26 2.731 40 116 (3) 100 (3) 507 (13)
27 2.731 41 151 (4) 417 (10) 1154 (28)
3 3.105 5.7 52 (9) 310 (54) 1087 (191)
4 3.634 4.2 36 (9) 426 (101) 495 (118)
DRV 2.387 5.5 33 (6) 320 (58) 1157 (210)
aNT: not tested. bcLogP values were calculated using ChemDraw 18.
cThe multidrug-resistant HIV-1 variants SLK19, VSL20, and KY24
contain the following amino acid substitutions in HIV-1 protease
compared to the WT NL4-3 strain: SLK19 (L10I, V11I, I13V, K14R,
A22V, E35D, M36I, N37D, G48M, F53L, I54V, I62V, L63P, A71V,
T74S, V82A, I84V, T91S, Q92K); VSL20 (L10I, K20R, L33F, E34A,
E35D, M36I, N37D, K43T, M46I, G48V, I50V, I54T, I62V, L63P,
A71V, I72V, V77I, V82A, I85V, I93L); KY24 (L10V, T12V, I13V,
I15V, K20M, V32I, L33F, K43T, M46I, I47V, I54M, D60E, Q61N,
I62V, L63P, C67Y, H69K, A71I, I72L, G73S, V77I, V82A, L89V,
L90M).
of 5.7 and 4.2 nM, respectively. The two analogues retained
potent activity against the SLK19 variant but were significantly
less potent against the VSL20 variant, with EC50 values similar
to that of DRV. Compared to DRV and compound 3, both of
which showed similar potencies against the three MDR
variants, analogue 4 retained 2-fold better potency against
the KY24 variant. The slightly improved resistance profile of
compound 4 is in agreement with previous results and
indicates that optimizing vdW interactions in the S1′ pocket
can improve potency against MDR viruses.23
All compounds incorporating the 4-(1-hydroxyethyl)-
benzene P2′ moieties (12−17) potently inhibited wild-type
HIV-1 with EC50 values similar to that of DRV and parent
compounds 3 and 4. However, the three MDR HIV-1 variants
showed distinct susceptibilities to each of these compounds,
depending on the P1′ group and the configuration of the
hydroxyethyl group at the P2′ moiety. Compound 12, with the
isobutyl P1′ group and the (S)-4-(1-hydroxyethyl)benzene P2′
moiety, was equipotent to DRV against SLK19 but exhibited
2−3-fold better potency against the highly resistant MDR
variants VSL20 and KY24, resulting in an overall improved
resistance profile. The corresponding epimer 13, incorporating
the (R)-4-(1-hydroxyethyl)benzene P2′ moiety, while showing
a 3-fold lower potency against SLK19, retained similar potency
as 12 against VSL20 and KY24. Diastereoisomers 14 and 15,
with the (S)-2-methylbutyl P1′ group, exhibited similar
potency profiles as the corresponding analogues 12 and 13,
except for a 2-fold loss in potency against VSL20. Further
improvement in overall potency profile was realized with
analogue 16, incorporating a larger 2-ethylbutyl P1′ group and
the (S)-4-(1-hydroxyethyl)benzene P2′ moiety, which main-
tained similar potency against SLK19 as DRV but demon-
strated about 3- and 6-fold increase in potency against VSL20
and KY24, respectively. Moreover, compared to the parent
compound 4, analogue 16 demonstrated 4- and 2-fold
improved potency against VSL20 and KY24. Compared to
16, the (R)-epimer 17 maintained similar potency against
SLK19 but exhibited lower potency against VSL20 and KY24.
While all compounds with the 4-(1-hydroxyethyl)benzene as
P2′ ligands maintained excellent potency against MDR HIV-1
variants, each exhibited a distinct resistance profile depending
Figure 2. Comparison of binding modes of protease inhibitors with 4-(1-hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene P2′ moieties in
the active site of wild-type HIV-1 protease. The two protease monomers are in cyan (denoted as nonprime) and magenta (denoted as prime).
Superposition of protease complexes with DRV (1), parent compounds (2−4), and new analogues (12−17 and 22−27). The inhibitors are shown
as sticks, and HIV-1 protease dimers are shown as ribbons. (B) Zoomed-in active site of superimposed complexes. The inhibitors bind to wild-type
HIV-1 protease in similar conformations except minor variations in the S2′ subsite. (C) Fit of inhibitors within the substrate envelope. The
substrate envelope is in blue space filling representation, and the superimposed inhibitors are displayed as sticks. There is minimal protrusion of
inhibitors outside the active site. (D) Variations in the binding mode of the inhibitors’ P2′ moieties.
on the configuration of the hydroxyethyl group and size of the
P1′ group.
The introduction of a more polar 4-(1,2-dihydroxyethyl)-
benzene moiety as the P2′ ligand resulted in significantly
reduced potency against wild-type HIV-1, despite compounds
22−27 showing pM inhibitory activities in biochemical assays.
The observed loss of potency in cellular assays is likely due to
reduced hydrophobicity, as indicated by lower calculated
partition coefficient (LogP) values compared to DRV (Table
1). The cellular potency of HIV-1 protease inhibitors has been
shown to strongly correlate with the hydrophobicity descriptor
LogP, suggesting that membrane transport is a key factor
affecting antiviral potency.35
The observed antiviral potencies of the 4-(1,2-
dihydroxyethyl)benzene containing compounds indeed corre-
late with their cLogP values (Figure S2). In all cases both
diastereoisomers exhibited similar antiviral potencies against
wild-type HIV-1. Compounds 22 and 23, incorporating the
isobutyl P1′ group, showed significantly lower potency than
DRV. Replacement of the isobutyl P1′ group with a slightly
more hydrophobic (S)-2-methylbutyl group, providing ana-
logues 24 and 25, resulted in further improvement in antiviral
potency. Compounds 26 and 27, incorporating a larger 2-
ethylbutyl P1′ group, further increased hydrophobicity and
resulted in a 2-fold improvement in potency compared to the
(S)-2-methylbuty P1′ analogues 24 and 25. However, both
diastereoisomers 26 and 27 were 8-fold less active than DRV
against wild-type HIV-1 despite 26 exhibiting similar potency
in enzyme inhibition assays. Compared to DRV the P2′ (R)-
epimer 26 maintained better potency against MDR variants
VSL20 and KY24 and exhibited much lower fold potency
losses. The corresponding (S)-epimer 27, though less active
against SLK19, showed similar potency as DRV against VSL20
and KY24. Thus, the combination of a more hydrophobic 2-
ethylbutyl P1′ group and the (R)-4-(1,2-dihydroxyethyl)-
benzene P2′ moiety provided compounds with improved
potency profiles.
Analysis of Protease-Inhibitor Complexes. To explore
molecular interactions of the chiral 4-(1-hydroxyethyl)benzene
and 4-(1,2-dihydroxyethyl)benzene P2′ moieties, we deter-
mined crystal structures of PIs 12−17 and 22−27 bound to
wild-type HIV-1 protease of the NL4-3 strain. The cocrystal
structures of PIs 2−4 were also determined with the same
protease enzyme, as the previously reported cocrystal
structures of PIs 3 and 4 were with the wild-type protease of
the SF-2 sequence, which is slightly different from NL4-3. The
Figure 3. Crystal structures of wild-type HIV-1 protease in complex with inhibitors (A) 16, (B) 17, (C) 26, and (D) 27. Both (R)- and (S)-
stereoisomers of the P2′ 4-(1-hydroxyethyl)benzene moiety make direct hydrogen bonding interactions with the backbone NH of Asp30′ in the
S2′ subsite (A and B). The (R)-stereoisomer of the P2′ 4-(1,2-dihydroxyethyl)benzene moiety makes hydrogen bonding interactions with the
backbone NH of Asp29′ and Asp30′ (C). The (S)-stereoisomer of the P2′ 4-(1,2-dihydroxyethyl)benzene moiety makes hydrogen bonding
interactions with the backbone NH and side chain carboxylate group of Asp30′ (D).
two variants differ by four amino acids, which caused minor
structural differences at the distal loops, but the active sites
were nearly identical, including inhibitor binding and crystallo-
graphic waters. The crystallographic data collection and
refinement statistics are summarized in Table S2. All 15
high-resolution (1.86−2.03 Å) cocrystal structures were solved
in the same P212121 space group with one protease homodimer
in the asymmetric unit, and only one orientation of the bound
inhibitor in the protease active site, which was crucial for direct
comparison and analysis.
The overall binding conformations of all PIs incorporating
the 4-(hydroxymethyl)benzene (2−4), 4-(1-hydroxyethyl)-
benzene (12−17), and 4-(1,2-dihydroxyethyl)benzene (22−
27) P2′ moieties are similar to that of DRV (Figure 2A).
However, clear differences in contacts were observed in the
binding of the P2′ moieties depending on the substituent at
the 4-position of the benzene ring and the configuration of the
hydroxyl group (Figure 2B, 2D). Compared to DRV, all PIs
with modified P2′ ligands maintain similar hydrogen bonding
interactions with the protease, except in the S2′ subsite
(Figures 3 and 4). The cocrystal structures of PIs 2−4 in
complex with protease showed minor changes in the
conformation of the 4-(hydroxymethyl)benzene moiety
compared to the 4-aminobenzene of DRV in the S2′ subsite
(Figure S3). In the DRV-bound protease structure, the amino
group of the 4-aminobenzene P2′ moiety is involved in
hydrogen bonding interactions with the main chain carbonyl of
Asp30′ and water-mediated interactions with the side-chain
carboxylate of Asp30′ (Figure S1). The primary hydroxyl
group of the 4-(hydroxymethyl)benzene P2′ moiety in
compounds 2−4 is oriented toward the Asp29′ and Asp30′
backbone and makes a direct hydrogen bond with the
backbone NH of Asp30′. Moreover, the hydroxyl group
interacts with the backbone NH of Asp29′ and the side chain
of Asp30′ through water-mediated hydrogen bonds. This
network of hydrogen bonding interactions in the S2′ subsite
likely underlies the improved potency of compounds 2−4
compared to DRV (Figure S1).
The PIs 12−17 with the 4-(1-hydroxyethyl)benzene moiety
at the P2′ position were designed to better position the
Figure 4. Comparison of binding interactions of representative PIs with modified P2′ moieties in the S2′ subsite of HIV-1 protease. Binding
interactions of (A) DRV (PDB 6DGX), (B) parent compound 4 (PDB 6OXQ) with the 4-(hydroxymethyl)benzene P2′ moiety, (C) inhibitor 16
with (S)-4-(1-hydroxyethyl)benzene P2′ moiety, (D) inhibitor 17 with the (R)-configuration of the P2′ moiety, (E) inhibitor 26 with (R)-4-(1,2-
dihydroxyethyl)benzene P2′ moiety, and (F) inhibitor 27 with the (S)-configuration of the P2′ moiety.
hydroxyl group between the backbone NH of Asp29′ and
Asp30′. In addition, the methyl group was expected to make
vdW interactions with the hydrophobic residues around the
S2′ subsite. Similar to the parent compounds, PIs 12−17 fit
well within the substrate envelope (Figure 2C). For both the
(S)- and (R)-4-(1-hydroxyethyl)benzene P2′ moieties only a
portion of the hydroxyethyl substituent protrudes outside the
envelope. The structures of PIs 12, 14, and 16 bound to
protease superimpose very well with the corresponding parent
compound structures with only subtle changes in the position
and orientation of the (S)-4-(1-hydroxyethyl)benzene P2′
moiety. The differences in the conformation of the P2′ moiety
are more evident for PIs 13, 15, and 17 incorporating the (R)-
4-(1-hydroxyethyl)benzene, which is shifted upward toward
the Gly48 backbone with a slight change in the orientation of
the benzene ring compared to the position in the
corresponding epimers, likely to maintain polar interactions
between the hydroxyl group and the backbone NH of Asp30′
(Figure S3).
Despite clear differences in the overall binding conforma-
tions of (S)- and (R)-4-(1-hydroxyethyl)benzene P2′ moieties,
the secondary hydroxyl group is oriented in the same direction
of the Asp29′ and Asp30′ backbone (Figure 4). Instead, the
orientation of the methyl group is altered. As a result,
regardless of the configuration of the hydroxyl group, the PIs
incorporating the 4-(1-hydroxyethyl)benzene moiety (12−17)
make identical direct and water-mediated hydrogen bonding
interactions in the protease active site as the parent
compounds 2−4 (Figure 4). In both configurations, the
hydroxyl group is positioned between the backbone NH of
Asp29′ and Asp30′. However, in all structures the hydroxyl
group makes a direct hydrogen bond only with the backbone
NH of Asp30′, which is closer (3.0−3.2 Å) than the NH of
Asp29′ (3.6−3.8 Å). The distance between the hydroxyl group
and the backbone NH of Asp30′ is slightly shorter (3.0−3.1 Å)
for compounds with the (S)-4-(1-hydroxyethyl)benzene P2′
moiety than the corresponding (R)-epimers (3.2 Å) (Table
S3). The hydroxyl group also interacts with the side chain of
Asp30′, mostly through water-mediated hydrogen bonds but
directly in the case of compound 14. In the 14-protease
complex structure the side chain of Asp30′ is shifted toward
the P2′ moiety, resulting in a strong, direct hydrogen bond
between the hydroxyl and carboxylate groups. Moreover, the
hydroxyl group makes water-mediated interactions with the
backbone NH of Asp29′, which are not observed in the DRV−
protease complex. Thus, the hydroxyl group at the P2′ moiety
is involved in a network of direct and water-mediated
interactions in the protease active site (Figure 4).
Cocrystal structures were analyzed for vdW contacts, and
compounds with the modified P2′ moieties showed enhanced
vdW interactions with protease residues in the S2′ subsite
compared to the corresponding parent PIs 2−4 (Figure 5). To
Figure 5. Packing of inhibitors (A) 16, (B) 17, (C) 26, and (D) 27 in the S2′ subsite of HIV-1 protease. The protease residues are colored blue to
red for increasing van der Waals (vdW) contact potentials with the inhibitor mapped onto the surface of cocrystal structures. Inhibitors and key
residues are shown as sticks.
evaluate the changes in vdW interactions, total vdW energies
per residue were calculated for each protease-inhibitor complex
and the corresponding values for parent compound subtracted
(Figure S5). The additional methyl group is oriented toward
Ile47 in complexes with PIs 12, 14, and 16 incorporating the
(S)-4-(1-hydroxyethyl)benzene P2′ moiety and toward Val32
and Leu76 in the corresponding (R)-epimers 13, 15, and 17.
Compounds with the same P1′ group show minor differences
in vdW interactions with residues in the S2′ subsite depending
on the configuration of the P2′ hydroxyl group. The methyl
group of analogue 12 with the (S)-configuration of the
hydroxyl group makes additional vdW interactions with the
methylene portion of the Asp30′ side chain compared to the
parent compound 2. Surprisingly, there is no increase in vdW
contacts with Ile47 even though the methyl group of
compound 12 is oriented toward this residue. The methyl
group of the P2′ (R)-epimer 13 forms vdW contacts with Ile47
and Leu76. The corresponding analogues with the (S)-2-
methylbutyl and 2-ethylbutyl P1′ groups showed largely similar
interactions as observed for 12 and 13, respectively, but a slight
shift in the benzene ring caused minor differences in the vdW
contacts. As previously shown for parent compounds 3 and 4,
larger (S)-2-methylbutyl and 2-ethylbutyl P1′ groups result in
increased vdW contacts in the S1′ subsite, compared to the
corresponding isobutyl group. Compounds with the same P1′
group show similar vdW contacts in the S1′ subsite. Thus,
enhanced vdW interaction of PIs 12−17 in the S2′ subsite
result from the additional methyl group and altered position of
the modified P2′ moiety.
While compounds with the (S)- and (R)-4-(1-
hydroxyethyl)benzene P2′ moieties show minor changes in
vdW contacts in the S2′ subsite, both diastereoisomers make
identical hydrogen bonding interactions with the protease
because the orientation of the hydroxyl group is similar in both
configurations. The largely similar overall binding interactions
of P2′ epimeric compounds correlate with the similar enzyme
inhibitory potencies observed between diastereoisomers. PIs
with the (S)-4-(1-hydroxyethyl)benzene P2′ moiety showed
improved antiviral potency against MDR variants likely due to
stronger polar interactions with the backbone atoms without
relying on contacts with side chains that could mutate to cause
resistance. Overall, the cocrystal structures provided insights
into the binding of these new PIs with modified P2′ moieties,
revealing the structural basis for the observed inhibitory
potencies.
The cocrystal structures of PIs 22−27, incorporating the 4-
(1,2-dihydroxyethyl)benzene in complex with protease,
revealed a larger shift in the position of the P2′ moiety
compared to DRV (Figure S3). The benzene ring is moved
toward the flaps, likely to accommodate the larger substituent
at the 4-position. With the (R)-configuration of the
dihydroxyethyl group, the primary hydroxyl group in PIs 22,
24, and 26 is oriented toward the Asp29′ backbone and the S3′
subsite. As a result, these PIs fit very well within the substrate
envelope (Figure 2C). In contrast, the primary hydroxyl group
in the corresponding (S)-epimer compounds 23, 25, and 27 is
oriented in the opposite direction, toward the Asp30′ and
Leu76 side chains, and lies largely outside the substrate
envelope. The cocrystal structures of PIs 22−27 also showed
subtle variations in the binding of the secondary hydroxyl
group of the (R)- and (S)-4-(1,2-dihydroxyethyl)benzene P2′
moieties. Despite differences in the binding of the dihydrox-
yethyl stereoisomers, similar conformations of the benzene ring
were observed for both (R)- and (S)-4-(1,2-dihydroxyethyl)-
benzene P2′ moieties.
The hydrogen bonding patterns of compounds incorporat-
ing the 4-(1,2-dihydroxyethyl)benzene as P2′ ligands varied
considerably depending on the configuration of the secondary
hydroxyl group (Figure 4). In the cocrystal structures of PIs
22, 24, and 26 with the (R)-configuration of the dihydrox-
yethyl group, the secondary hydroxyl group makes a strong,
direct hydrogen bond with the backbone NH of Asp30′.
Another weaker but direct hydrogen bond connects the
secondary hydroxyl group with the side chain carboxylate of
Asp30′, replacing the water-mediated interactions observed for
compounds with the 4-(hydroxymethyl)- and 4-(1-hydrox-
yethyl)-benzene P2′ moieties. The primary hydroxyl group of
the (R)-dihydroxyethyl moiety is oriented toward the protease
backbone and forms a direct hydrogen bond with the
backbone NH of Asp29′, displacing a water molecule observed
in the parent compound structures (Figure S4). The primary
hydroxyl group is also involved in weaker (3.3−3.5 Å), direct
hydrogen bonding interactions with the side chain carboxylate
of Asp29′. The unique pattern of polar interactions of the (R)-
dihydroxyethyl group in the S2′ subsite, particularly involving
the backbone NH of Asp29′ and Asp30′, mimics the
interactions of the bis-THF moiety in the S2 subsite.
The cocrystal structures of PIs 23, 25, and 27 with the (S)-
configuration of the P2′ dihydroxyethyl group also revealed a
unique network of hydrogen bonds between the hydroxyl
groups and the protease. The secondary hydroxyl group forms
two direct hydrogen bonds, one with the backbone NH of
Asp30′ and another with the side chain carboxylate of the same
residue. The secondary hydroxyl group is also positioned close
to the backbone NH of Asp29′ (3.5−3.6 Å) and makes water-
mediated interactions with both the backbone NH and side
chain carboxylate of this residue. The primary hydroxyl group
is oriented toward the side chain of Asp30′ and is involved in a
direct hydrogen bonding interaction with the carboxyl group,
replacing the water molecule observed in complexes with
compounds incorporating the 4-(hydroxymethyl)- and 4-(1-
hydroxyethyl)-benzene P2′ moieties. In this orientation, the
dihydroxyethyl group forms an additional direct hydrogen
bond with the protease replacing a water-mediated interaction.
In addition, PIs 22−27, incorporating the 4-(1,2-
dihydroxyethyl)benzene moieties as P2′ ligands, form
enhanced vdW contacts with the protease compared to the
corresponding parent compounds 2−4. The altered position of
the P2′ moiety places the benzene ring closer to Gly48′ in the
flaps, resulting in an overall increase in vdW contacts for all PIs
in this series. Minor changes in vdW interactions were
observed between P2′ epimeric compounds, with additional
subtle variations resulting from changes at the P1′ position
(Figure S5). In general, compounds with the (R)-configuration
of the modified P2′ moiety (22, 24, and 26) make enhanced
vdW interactions with Asp29′, Pro81, and residues 47′−50′ in
the flap region but slightly reduced interactions with Val32 and
Ile84 (Figure 5). The corresponding (S)-epimers (23, 25, and
27) formed more vdW contacts with a different set of residues
around the active site, including Asp30′, Lys45′, Ile47, and
Leu76′, and weaker contacts with Asp30 and Ile50. However,
few exceptions to these general trends were observed for
compounds 24 and 25 that incorporate the (S)-2-methylbutyl
group at the P1′ position, likely due to the asymmetric shape of
the P1′ group (Figure S5). Overall, for PIs incorporating the 4-
(1,2-dihydroxyethyl)benzene P2′ moieties, the increase in vdW
interactions with specific protease residues mainly depends on
the configuration of the dihydroxyethyl group.
The cocrystal structures of PIs with the 4-(1,2-
dihydroxyethyl)benzene P2′ moieties revealed unique hydro-
gen bonding patterns and vdW contacts that vary significantly,
depending on the configuration of the modified P2′ moiety.
The improved potency profiles of PIs with the (R)-4-(1,2-
dihydroxyethyl)benzene P2′ moiety compared to the corre-
sponding (S)-epimers likely result from enhanced backbone
interactions with residues Asp29′ and Asp30′, as well as
increased vdW contacts with the side chains of Asp29′ and
residues in the flap region. Notably, these PIs also fit very well
in the substrate envelope. Compound 26, with the 2-ethylbutyl
P1′ group, is a promising lead for exploring further
modifications, particularly in combination with more hydro-
phobic P1 and P2 groups, to further improve potency against
MDR variants.
■ CONCLUSIONS
New HIV-1 protease inhibitors were designed by incorporating
stereoisomers of the 4-(1-hydroxyethyl)benzene and 4-(1,2-
dihydroxyethyl)benzene moieties as P2′ ligands to enhance
hydrogen bonding interactions in the S2′ subsite. Compounds
with the polar dihydroxyethyl group at the P2′ moiety were
generally less potent than DRV while inhibitors with the
hydroxyethyl group exhibited improved antiviral potency
against MDR variants. Crystal structures of protease−inhibitor
complexes show that all PIs make enhanced hydrogen bonding
and vdW interactions with the protease. The reduced cellular
potency of PIs with the dihydroxyethyl group is likely due to
their relatively low hydrophobicity, which can be counter-
balanced with increased hydrophobicity at other positions such
as P1. Overall, the PI potency profile was determined by the
polar substituent at the 4-position of the P2′ benzene ring, the
configuration of the secondary hydroxyl group, and the size of
the P1′ group. Exploration of both stereoisomers of the P2′
moiety revealed unique polar and vdW interactions, including a
network of direct and water-mediated hydrogen bonding with
the backbone and side chain atoms of Asp29′ and Asp30′.
Notably, PIs with the (R)-4-(1,2-dihydroxyethyl)benzene
moiety make hydrogen bonding interactions with the back-
bone NH of Asp29′ and Asp30′ in the S2′ subsite, mimicking
the polar interactions of the P2 bis-THF moiety, and show
improved potency and resistance profiles compared to the
corresponding (S)-epimers. In general, compounds that make
increased hydrogen bonding interactions with the backbone
and vdW contacts with invariant residues and fit better within
the substrate envelope maintain better potency against highly
resistant MDR HIV-1 strains. These SAR data and structural
insights may allow further optimization of these promising
inhibitors.
■ EXPERIMENTAL SECTION
General. All reactions were performed in oven-dried round-
bottom flasks fitted with rubber septa under argon atmosphere unless
otherwise noted. All reagents and solvents, including anhydrous
solvents, were purchased from commercial sources and used as
received. Flash column chromatography was performed on an
automated Teledyne ISCO CombiFlash Rf+ system equipped with
a UV−vis detector using disposable Redisep Gold high performance
silica gel columns or was performed manually using silica gel (230−
400 mesh, EMD Millipore). Thin-layer chromatography (TLC) was
performed using silica gel (60 F254) coated aluminum plates (EMD
Millipore), and spots were visualized by exposure to ultraviolet light
(UV), exposure to iodine adsorbed on silica gel, and/or staining with
alcohol solutions of phosphomolybdic acid (PMA) and ninhydrin
followed by brief heating. 1H NMR and 13C NMR spectra were
acquired on Varian Mercury 400 MHz and Bruker Avance III HD 500
MHz NMR instruments. Chemical shifts are reported in ppm (δ
scale) with the residual solvent signal used as reference, and coupling
constant (J) values are reported in hertz (Hz). Data are presented as
follows: chemical shift, multiplicity (s = singlet, d = doublet, dd =
doublet of doublet, dt = doublet of triplet, t = triplet, m = multiplet, br
s = broad singlet), coupling constant in Hz, and integration. High-
resolution mass spectra (HRMS) were recorded on a Thermo
Scientific Orbitrap Velos Pro mass spectrometer coupled with a
Thermo Scientific Accela 1250 UPLC and an autosampler using
electrospray ionization (ESI) in the positive mode. The purity of final
compounds was determined by analytical HPLC and was found to be
≥95% pure. HPLC was performed on a Agilent 1200 system equipped
with a multiple wavelength detector and a manual injector under the
following conditions: column, Phenomenex Hypersil-BDS-5u-C18 (5
μm, 4.6 mm × 250 mm, 130 Å); solvent A, H2O containing 0.1%
trifluoroacetic acid (TFA); solvent B, CH3CN containing 0.1% TFA;
gradient, 20% B to 100% B over 15 min followed by 100% B over 5
min; injection volume, 20 μL; flow rate, 1 mL/min. The wavelengths
of detection were 254 nm and 280 nm. Retention times and purity
data for each target compound are provided in the Experimental
Section.
Synthesis of Protease Inhibitors. tert-Butyl ((2S,3R)-3-
Hydroxy-4- ( (4- ( (S ) -1-hydroxyethyl ) -N- isobuty lphenyl ) -
sulfonamido)-1-phenylbutan-2-yl)carbamate (9a). A solution of
tert-butyl ((2S,3R)-4-((4-acetyl-N-isobutylphenyl)sulfonamido)-3-hy-
droxy-1-phenylbutan-2-yl)carbamate 8a (1.00 g, 1.93 mmol) in
anhydrous tetrahydrofuran (40 mL) was cooled to 0 °C, and the
(R)-2-methyl-CBS-oxazaborolidine (1.07 g, 3.86 mmol) catalyst was
added. After stirring the reaction mixture for 15 min, borane solution
(1 M in THF) (2.90 mL, 2.90 mmol) was added dropwise over an
hour. Stirring was continued at 0 °C until the reaction was complete,
as indicated by TLC. The reaction was quenched with an acetone/
methanol mixture (1:1, 20 mL) and the solvent was removed under
reduced pressure. The crude product was purified by automated flash
chromatography using a silica gel column (RediSep Gold, 40 g,
gradient elution with 0−100% EtOAc/hexanes), to give compound 9a
as a white solid. Recrystallization from a mixture of ethyl acetate/
hexanes (1:1) provided a white solid (0.77 g, 77%). 1H NMR (500
MHz, CDCl3) δ 7.74 (d, J = 8.4 Hz, 2 H), 7.51 (d, J = 8.3 Hz, 2 H),
7.31−7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 5.00−4.95 (m, 1 H), 4.63
(d, J = 7.5 Hz, 1 H), 3.92 (s, 1 H), 3.82−3.71 (m, 2 H), 3.13−3.05
(m, 2 H), 3.02−2.80 (m, 4 H), 2.02 (d, J = 3.5 Hz, 1 H), 1.89−1.81
(m, 1 H), 1.51 (d, J = 6.5 Hz, 3 H), 1.34 (s, 9 H), 0.91 (d, J = 6.5 Hz,
3 H), 0.87 (d, J = 7.0 Hz, 3 H) ppm. 13C NMR (125 MHz, CDCl3) δ
156.20, 151.19, 137.93, 137.24, 129.67, 128.60, 127.72, 126.57,
126.22, 79.87, 72.91, 69.72, 58.76, 54.84, 53.81, 35.58, 28.37, 27.30,
25.54, 20.23, 19.99 ppm. HRMS (ESI) m/z: [M + H]+ calcd for
C27H41N2O6S, 521.2680; found 521.2676.
tert-Butyl ((2S,3R)-3-Hydroxy-4-((4-((S)-1-hydroxyethyl)-N-((S)-2-
methylbutyl)phenyl)sulfonamido)-1-phenylbutan-2-yl)carbamate
(9b). The same procedure was used as described above for compound
9a. Compound 8b (1.00 g, 1.88 mmol) was treated with (R)-2-
methyl-CBS-oxazaborolidine (1.04 g, 3.75 mmol) and borane solution
(1 M in THF) (2.82 mL, 2.82 mmol) to give compound 9b as a white
solid (yield after recrystallization: 0.57 g, 57%). 1H NMR (500 MHz,
CDCl3) δ 7.74 (d, J = 8.4 Hz, 2 H), 7.51 (d, J = 8.3 Hz, 2 H), 7.31−
7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 5.00−4.95 (m, 1 H), 4.61 (d, J =
6.5 Hz, 1 H), 3.87 (s, 1 H), 3.80−3.71 (m, 2 H), 3.13−2.89 (m, 5 H),
2.82 (dd, J = 13.0, 7.0 Hz, 1 H), 2.00 (d, J = 3.7 Hz, 1 H), 1.64−1.58
(m, 1 H), 1.51 (d, J = 6.5 Hz, 3 H), 1.50−1.44 (m, 1 H, overlapping),
1.34 (s, 9 H), 1.11−1.02 (m, 1 H), 0.86−0.83 (m, 6 H) ppm. 13C
NMR (125 MHz, CDCl3) δ 156.18, 151.11, 137.85, 137.26, 129.72,
128.64, 127.78, 126.61, 126.22, 79.88, 72.83, 69.80, 57.39, 54.74,
53.80, 35.59, 33.50, 28.40, 26.56, 25.58, 17.02, 11.17 ppm. HRMS




(9c). The same procedure was used as described above for compound
9a. Compound 8c (1.00 g, 1.83 mmol) was treated with (R)-2-
methyl-CBS-oxazaborolidine (1.01 g, 3.66 mmol) and borane solution
(1 M in THF) (2.74 mL, 2.74 mmol) to give compound 9c as a white
solid (yield after recrystallization: 0.85 g, 85%). 1H NMR (500 MHz,
CDCl3) δ 7.74 (d, J = 8.4 Hz, 2 H), 7.52 (d, J = 8.3 Hz, 2 H), 7.31−
7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 5.00−4.96 (m, 1 H), 4.58 (d, J =
5.9 Hz, 1 H), 3.92 (s, 1 H), 3.75 (m, 2 H), 3.12−2.98 (m, 4 H),
2.92−2.86 (m, 2 H), 2.01 (d, J = 3.7 Hz, 1 H), 1.51 (d, J = 6.5 Hz, 3
H), 1.49−1.37 (m, 2 H), 1.34 (s, 9 H), 1.34−1.24 (m, 3 H,
overlapping), 0.83−0.79 (m, 6 H) ppm. 13C NMR (125 MHz,
CDCl3) δ 156.16, 151.13, 137.83, 137.14, 129.71, 128.63, 127.81,
126.60, 126.24, 79.86, 73.06, 69.80, 54.91, 54.69, 53.81, 39.09, 35.77,
28.40, 25.58, 23.18, 22.86, 10.70, 10.42 ppm. HRMS (ESI) m/z: [M
+ H]+ calcd for C29H45N2O6S, 549.2993; found 549.2989.
tert-Butyl ((2S,3R)-3-Hydroxy-4-((4-((R)-1-hydroxyethyl)-N-
isobutylphenyl)sulfonamido)-1-phenylbutan-2-yl)carbamate
(10a). The same procedure was used as described above for
compound 9a. Compound 8a (1.00 g, 1.93 mmol) was treated with
(S)-2-methyl-CBS-oxazaborolidine (1.22 g, 4.40 mmol) and borane
solution (1 M in THF) (3.3 mL, 3.30 mmol) to give compound 10a
as a white solid (yield after crystallization: 0.6 g, 60%). 1H NMR (500
MHz, CDCl3) δ 7.72 (d, J = 8.4 Hz, 2 H), 7.50 (d, J = 8.3 Hz, 2 H),
7.30−7.27 (m, 2 H), 7.24−7.19 (m, 3 H), 4.98−4.93 (m, 1 H), 4.67
(d, J = 7.8 Hz, 1 H), 3.94 (s, 1 H), 3.84−3.70 (m, 2 H), 3.12−3.04
(m, 2 H), 3.01−2.80 (m, 4 H), 2.35 (s, 1 H), 1.89−1.81 (m, 1 H),
1.49 (d, J = 6.5 Hz, 3 H), 1.33 (s, 9 H), 0.90 (d, J = 7.0 Hz, 3 H), 0.86
(d, J = 6.5 Hz, 3 H) ppm. 13C NMR (125 MHz, CDCl3) δ 156.20,
151.23, 137.94, 137.19, 129.66, 128.59, 127.69, 126.55, 126.21, 79.85,
72.91, 69.67, 58.74, 54.83, 53.80, 35.57, 28.36, 27.28, 25.54, 20.22,




(10b). The same procedure was used as described above for
compound 9a. Compound 8b (1.00 g, 1.88 mmol) was treated with
(S)-2-methyl-CBS-oxazaborolidine (1.04 g, 3.75 mmol) and borane
solution (1 M in THF) (2.82 mL, 2.82 mmol) to give 10b as a white
solid (yield after recrystallization: 0.76 g, 76%). 1H NMR (500 MHz,
CDCl3) δ 7.74 (d, J = 8.4 Hz, 2 H), 7.52 (d, J = 8.3 Hz, 2 H), 7.31−
7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 5.00−4.96 (m, 1 H), 4.61 (d, J =
6.7 Hz, 1 H), 3.87 (s, 1 H), 3.82−3.71 (m, 2 H), 3.13−2.99 (m, 5 H),
2.82 (d, J = 13.0, 7.0 Hz, 1 H), 1.95 (d, J = 3.5 Hz, 1 H), 1.64−1.57
(m, 1 H), 1.51 (d, J = 6.5 Hz, 3 H), 1.51−1.44 (m, 1 H, overlapping),
1.35 (s, 9 H), 1.11−1.02 (m, 1 H), 0.86−0.83 (m, 6 H) ppm. 13C
NMR (125 MHz, CDCl3) δ 156.18, 151.09, 137.85, 137.28, 129.72,
128.65, 127.80, 126.61, 126.22, 79.88, 72.82, 69.82, 57.41, 54.73,
53.82, 35.60, 33.51, 28.41, 26.56, 25.60, 17.02, 11.17 ppm. HRMS




(10c). The same procedure was used as described above for
compound 9a. Compound 8c (1.00 g, 1.83 mmol) was treated with
(S)-2-methyl-CBS-oxazaborolidine (1.01 g, 3.66 mmol) and borane
solution (1 M in THF) (2.74 mL, 2.74 mmol) to give compound 10c
as a white solid (yield after recrystallization: 0.71 g, 69%). 1H NMR
(500 MHz, CDCl3) δ 7.75 (d, J = 8.5 Hz, 2 H), 7.52 (d, J = 8.3 Hz, 2
H), 7.31−7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 5.00−4.96 (m, 1 H),
4.58 (d, J = 5.5 Hz, 1 H), 3.93 (s, 1 H), 3.79−3.71 (m, 2 H), 3.12−
2.99 (m, 4 H), 2.92−2.85 (m, 2 H), 1.96 (d, J = 3.4 Hz, 1 H), 1.51 (d,
J = 6.5 Hz, 3 H), 1.48−1.37 (m, 2 H), 1.34 (s, 9 H), 1.34−1.18 (m, 3
H, overlapping), 0.83−0.79 (m, 6 H) ppm. 13C NMR (125 MHz,
CDCl3) δ 156.15, 151.09, 137.83, 137.15, 129.72, 128.64, 127.82,
126.60, 126.24, 79.86, 73.07, 69.83, 54.93, 54.68, 53.83, 39.10, 35.78,
28.40, 25.60, 23.18, 22.86, 10.70, 10.42 ppm. HRMS (ESI) m/z: [M
+ H]+ calcd for C29H45N2O6S, 549.2993; found 549.2992.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-3-Hy-
droxy-4-((4-((S)-1-hydroxyethyl)-N-isobutylphenyl)sulfonamido)-1-
phenylbutan-2-yl)carbamate (12). A solution of compound 9a (0.45
g, 0.864 mmol) in anhydrous dichloromethane (6 mL) was treated
with trifluoroacetic acid (5 mL). After the reaction mixture was stirred
at room temperature for 1 h, solvents were evaporated under reduced
pressure and the residue was dried under high vacuum. A solution of
the resulting amine salt in anhydrous acetonitrile (15 mL) was cooled
to 0 °C and treated with diisopropylethylamine (0.34 g, 2.59 mmol)
followed by bis-THF activated carbonate 11 (0.23 g, 0.864 mmol).
After 15 min, the reaction mixture was allowed to warm to room
temperature and stirred for 24 h. The solvents were removed under
reduced pressure, and the residue was purified by automated flash
chromatography using a silica gel column (RediSep Gold, 24 g,
gradient elution with 0−10% methanol/dichloromethane) to give the
target compound 12 (0.44 g, 88%) as a white solid. 1H NMR (500
MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 2 H), 7.54 (d, J = 8.2 Hz, 2 H),
7.30−7.27 (m, 2 H), 7.22−7.19 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1 H),
5.02−4.96 (m, 2 H), 4.90 (d, J = 8.4 Hz, 1 H), 3.96−3.83 (m, 4 H),
3.70−3.65 (m, 2 H), 3.60 (br s, 1 H), 3.19−3.14 (m, 1 H), 3.08 (dd, J
= 14.0, 3.6 Hz, 1 H), 3.03−2.97 (m, 2 H), 2.92−2.77 (m, 3 H), 2.06
(br s, 1 H), 1.87−1.81 (m, 1 H), 1.68−1.57 (m, 1 H), 1.52 (d, J = 6.5
Hz, 3 H, overlapping), 1.51−1.47 (m, 1 H), 0.94 (d, J = 6.6 Hz, 3 H),
0.89 (d, J = 6.6 Hz, 3 H) ppm. 13C NMR (100 MHz, CDCl3) δ
155.60, 151.33, 137.63, 136.92, 129.48, 128.72, 127.74, 126.77,
126.34, 109.44, 73.59, 72.95, 70.98, 69.74, 59.09, 55.21, 53.96, 45.44,
35.79, 27.46, 25.99, 25.59, 20.29, 20.00 ppm. HRMS (ESI) m/z: [M
+ H]+ calcd for C29H41N2O8S, 577.2578; found 577.2575. Anal.
HPLC: tR 11.22 min, purity 97%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-3-Hy-
droxy-4-((4-((R)-1-hydroxyethyl)-N-isobutylphenyl)sulfonamido)-1-
phenylbutan-2-yl)carbamate (13). The same procedure was used as
described above for compound 12. Compound 10a (0.40 g, 0.768
mmol) was treated with trifluoroacetic acid (5 mL), and the resulting
deprotected amine was treated with diisopropylethylamine (0.30 g,
2.304 mmol) and bis-THF activated carbonate 11 (0.21 g, 0.768
mmol) to give compound 13 (0.40 g, 90%) as a white solid. 1H NMR
(500 MHz, CDCl3) δ 7.74 (d, J = 8.3 Hz, 2 H), 7.53 (d, J = 8.3 Hz, 2
H), 7.29−7.26 (m, 2 H), 7.22−7.19 (m, 3 H), 5.63 (d, J = 5.2 Hz, 1
H), 5.01−4.95 (m, 3 H), 3.94−3.81 (m, 4 H), 3.69−3.60 (m, 3 H),
3.17−3.12 (m, 1 H), 3.08 (dd, J = 14.0, 3.6 Hz, 1 H), 3.05−2.96 (m,
2 H), 2.90−2.76 (m, 3 H), 2.27 (br s, 1 H), 1.89−1.81 (m, 1 H),
1.66−1.58 (m, 1 H), 1.50 (d, J = 6.5 Hz, 3 H, overlapping), 1.50−
1.44 (m, 1 H), 0.93 (d, J = 6.6 Hz, 3 H), 0.89 (d, J = 6.6 Hz, 3 H)
ppm. 13C NMR (100 MHz, CDCl3) δ 155.59, 151.34, 137.62, 136.89,
129.48, 128.73, 127.76, 126.78, 126.32, 109.44, 73.61, 72.95, 71.01,
69.75, 59.14, 55.21, 54.01, 45.43, 35.83, 27.47, 26.00, 25.62, 20.29,
20.00 ppm. HRMS (ESI) m/z: [M + H]+ calcd for C29H41N2O8S,
577.2578; found 577.2581. Anal. HPLC: tR 11.37 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-3-Hy-
droxy-4-((4-((S)-1-hydroxyethyl)-N-((S)-2-methylbutyl)phenyl)-
sulfonamido)-1-phenylbutan-2-yl)carbamate (14). The same pro-
cedure was used as described above for compound 12. Compound 9b
(0.43 g, 0.804 mmol) was treated with trifluoroacetic acid (5 mL),
and the resulting deprotected amine was treated with diisopropyle-
thylamine (0.31 g, 2.41 mmol) and bis-THF activated carbonate 11
(0.22 g, 0.804 mmol) to give compound 14 (0.41 g, 86%) as a white
solid. 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2 H), 7.53
(d, J = 8.2 Hz, 2 H), 7.30−7.27 (m, 2 H), 7.22−7.20 (m, 3 H), 5.64
(d, J = 5.2 Hz, 1 H), 5.03−4.96 (m, 2 H), 4.89 (d, J = 8.9 Hz, 1 H),
3.94 (dd, J = 9.5, 6.0 Hz, 1 H), 3.91−3.83 (m, 3 H), 3.71− 3.65 (m, 2
H), 3.56 (br s, 1 H), 3.17−2.98 (m, 4 H), 2.92−2.87 (m, 1 H), 2.84−
2.80 (m, 2 H), 2.10 (br s, 1 H), 1.69−1.59 (m, 2 H), 1.54−1.46 (m, 2
H), 1.51 (d, J = 6.5 Hz, 3 H, overlapping), 1.14−1.05 (m, 1 H), 0.88−
0.85 (m, 6 H) ppm. 13C NMR (125 MHz, CDCl3) δ 155.61, 151.35,
137.60, 136.93, 129.52, 128.74, 127.77, 126.79, 126.33, 109.44, 73.62,
72.83, 70.98, 69.73, 57.60, 55.20, 53.90, 45.46, 35.81, 33.63, 26.54,
25.98, 25.57, 17.05, 11.18 ppm. HRMS (ESI) m/z: [M + H]+ calcd




sulfonamido)-1-phenylbutan-2-yl)carbamate (15). The same pro-
cedure was used as described above for compound 12. Compound
10b (0.40 g, 0.748 mmol) was treated with trifluoroacetic acid (5
mL), and the resulting deprotected amine was treated with
diisopropylethylamine (0.29 mg, 2.24 mmol) and bis-THF activated
carbonate 11 (0.20 g, 0.748 mmol) to give compound 15 (0.40 g,
91%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.4
Hz, 2 H), 7.54 (d, J = 8.3 Hz, 2 H), 7.30−7.27 (m, 2 H), 7.23−7.20
(m, 3 H), 5.65 (d, J = 5.2 Hz, 1 H), 5.03−4.96 (m, 2 H), 4.86 (d, J =
9.0 Hz, 1 H), 3.94 (dd, J = 9.5, 6.0 Hz, 1 H), 3.91−3.84 (m, 3 H),
3.72−3.64 (m, 2 H), 3.55 (br s, 1 H), 3.14 (dd, J = 15.0, 8.5 Hz, 1 H),
3.10−3.04 (m, 2 H), 2.99 (dd, J = 15.0, 3.0 Hz, 1 H), 2.92−2.87 (m,
1 H), 2.85−2.80 (m, 2 H), 2.05 (br s, 1 H), 1.70−1.55 (m, 2 H),
1.54−1.47 (m, 2 H), 1.52 (d, J = 6.5 Hz, 3 H, overlapping), 1.14−
1.05 (m, 1 H), 0.88−0.85 (m, 6 H) ppm. 13C NMR (125 MHz,
CDCl3) δ 155.61, 151.38, 137.59, 136.90, 129.52, 128.74, 127.78,
126.80, 126.31, 109.45, 73.62, 72.83, 71.01, 69.73, 57.64, 55.19, 53.93,
45.46, 35.85, 33.64, 26.56, 25.99, 25.59, 17.05, 11.18 ppm. HRMS
(ESI) m/z: [M + H]+ calcd for C30H43N2O8S, 591.2735; found
591.2734. Anal. HPLC: tR 11.87 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-((N-(2-
Ethylbutyl)-4-((S)-1-hydroxyethyl)phenyl)sulfonamido)-3-hydroxy-
1-phenylbutan-2-yl)carbamate (16). The same procedure was used
as described above for compound 12. Compound 9c (0.40 g, 0.729
mmol) was treated with trifluoroacetic acid (5 mL), and the resulting
deprotected amine was treated with diisopropylethylamine (0.28 g,
2.19 mmol) and bis-THF activated carbonate 11 (0.22 g, 0.801
mmol) to give compound 16 (0.36 g, 82%) as a white solid. 1H NMR
(500 MHz, CDCl3) δ 7.75 (d, J = 8.4 Hz, 2 H), 7.54 (d, J = 8.3 Hz, 2
H), 7.30−7.27 (m, 2 H), 7.22−7.20 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1
H), 5.02−4.97 (m, 2 H), 4.84 (d, J = 9.1 Hz, 1 H), 3.94 (d, J = 9.5,
6.0 Hz, 1 H), 3.88−3.80 (m, 3 H), 3.70−3.64 (m, 3 H), 3.17−3.06
(m, 3 H), 2.98 (dd, J = 15.0, 3.0 Hz, 1 H), 2.92−2.85 (m, 2 H), 2.81
(dd, J = 14.0, 9.0 Hz, 1 H), 2.02 (br s, 1 H), 1.68−1.60 (m, 1 H),
1.55−1.42 (m, 3 H), 1.52 (d, J = 6.5 Hz, 3H, overlapping), 1.35−1.25
(m, 3 H), 0.85−0.81 (m, 6 H) ppm. 13C NMR (100 MHz, CDCl3) δ
155.58, 151.34, 137.57, 136.69, 129.50, 128.74, 127.79, 126.78,
126.35, 109.43, 73.60, 73.19, 70.91, 69.75, 55.11, 53.95, 45.44, 39.26,
35.93, 25.97, 25.59, 23.16, 22.85, 10.77, 10.41 ppm. HRMS (ESI) m/
z: [M + H]+ calcd for C31H45N2O8S, 605.2891; found 605.2890. Anal.
HPLC: tR 12.56 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-((N-(2-
Ethylbutyl)-4-((R)-1-hydroxyethyl)phenyl)sulfonamido)-3-hydroxy-
1-phenylbutan-2-yl)carbamate (17). The same procedure was used
as described above for compound 12. Compound 10c (0.40 g, 0.729
mmol) was treated with trifluoroacetic acid (5 mL), and the resulting
deprotected amine was treated with diisopropylethylamine (0.28 g,
2.19 mmol) and bis-THF activated carbonate 11 (0.28 g, 0.801
mmol) to give compound 17 (0.32 g, 73%) as a white solid. 1H NMR
(500 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2 H), 7.54 (d, J = 8.2 Hz, 2
H), 7.30−7.27 (m, 2 H), 7.23−7.20 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1
H), 5.02−4.97 (m, 2 H), 4.84 (d, J = 8.5 Hz, 1H), 4.93 (dd, J = 10.0,
6.5 Hz, 1H), 3.87−3.80 (m, 3 H), 3.71− 3.64 (m, 3 H), 3.16−3.06
(m, 3 H), 2.99−2.96 (dd, J = 15.5, 2.5 Hz, 1 H), 2.92−2.86 (m, 2 H),
2.80 (dd, J = 14.0, 9.2 Hz, 1 H), 2.06 (br s, 1 H), 1.66−1.60 (m, 1 H),
1.53−1.40 (m, 3 H), 1.52 (d, J = 6.5 Hz, 3H, overlapping), 1.35−1.25
(m, 3 H), 0.85−0.81 (m, 6 H) ppm. 13C NMR (100 MHz, CDCl3) δ
155.57, 151.46, 137.65, 136.56, 129.45, 128.65, 127.71, 126.68,
126.29, 109.40, 73.51, 73.18, 70.95, 69.72, 69.59, 55.16, 54.97, 53.81,
45.45, 39.12, 35.90, 25.94, 25.52, 23.07, 22.81, 10.67, 10.40 ppm.
HRMS (ESI) m/z: [M + H]+ calcd for C31H45N2O8S, 605.2891;
found 605.2891. Anal. HPLC: tR 12.61 min, purity 100%.
tert-Butyl ( (2S,3R)-4-( (4-( (R)-1 ,2-Dihydroxyethyl ) -N-
isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)-
carbamate (20a). t-Butanol (7.5 mL) and water (7.5 mL) were
charged into a round-bottom flask, and AD-mix-ß (2.80 g) was added.
The mixture was stirred at room temperature until two clear phases
appeared. The mixture was cooled to 0 °C, and intermediate 19a
(0.86 g, 1.71 mmol) was added in one portion. The resulting reaction
mixture was stirred at 4 °C for 48 h. Reaction was quenched by
adding sodium sulfite (3.00 g), and the mixture was allowed to warm
to room temperature. Ethyl acetate (10 mL) was added, phases were
separated, and the aqueous layer was extracted with ethyl acetate (3 ×
10 mL). The combined organic portions were dried (Na2SO4),
filtered, and concentrated. The residue was purified by automated
flash chromatography using a silica gel column (RediSep Gold, 40 g,
gradient elution with 20−100% ethyl acetate/hexanes) to give
compound 20a as a white solid (0.80 g, 87%). 1H NMR (500
MHz, CDCl3) δ 7.75 (d, J = 8.4 Hz, 2 H), 7.52 (d, J = 8.3 Hz, 2 H),
7.31−7.28 (m, 2 H), 7.24−7.20 (m, 3 H), 4.88 (d, J = 6.0 Hz, 1 H),
4.65 (d, J = 7.4 Hz, 1 H), 3.93 (s, 1 H), 3.83−3.70 (m, 3 H), 3.62
(dd, J = 11.0, 8.0 Hz, 1 H), 3.14−3.07 (m, 2 H), 3.01−2.82 (m, 5 H),
2.31 (s, 1 H), 1.89−1.81 (m, 1 H), 1.34 (s, 9 H), 0.90 (d, J = 6.5 Hz,
3 H), 0.86 (d, J = 6.5 Hz, 3 H) ppm. 13C NMR (125 MHz, CDCl3) δ
156.27, 145.97, 137.93, 137.89, 129.67, 128.64, 127.68, 126.97,
126.62, 79.99, 74.00, 72.88, 67.88, 58.70, 54.89, 53.73, 35.58, 28.39,
27.30, 20.24, 20.00 ppm. HRMS (ESI) m/z: [M + H]+ calcd for
C27H41N2O7S, 537.2629; found 537.2627.
tert-Butyl ((2S,3R)-4-((4-((R)-1,2-Dihydroxyethyl)-N-((S)-2-
methylbutyl)phenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)-
carbamate (20b). The same procedure was used as described above
for compound 20a. Compound 19b (1.22 g, 2.36 mmol) was treated
with AD-mix-ß (2.80 g) and the reaction was quenched with solid
sodium sulfite (3.00 g) to give compound 20b as a white solid (0.88 g,
68%). 1H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.5 Hz, 2 H), 7.48
(d, J = 8.0 Hz, 2 H), 7.29−7.25 (m, 2 H), 7.22−7.18 (m, 3 H), 4.84−
4.82 (m, 1 H), 4.74 (d, J = 7.4 Hz, 1 H), 3.97 (s, 1 H), 3.80−3.69 (m,
4 H), 3.58−3.55 (m, 1 H), 3.14−3.04 (m, 3 H), 3.02−2.93 (m, 2 H),
2.90−2.79 (m, 2 H), 1.64−1.57 (m, 1 H), 1.47−1.39 (m, 1 H), 1.32
(s, 9 H), 1.08−0.99 (m, 1 H), 0.84−0.81 (m, 6 H) ppm. 13C NMR
(125 MHz, CDCl3) δ 156.23, 146.24, 137.77, 137.59, 129.60, 128.58,
127.55, 126.96, 126.57, 79.97, 73.94, 72.64, 67.80, 57.09, 54.78, 53.46,
35.60, 33.37, 28.33, 26.55, 16.95, 11.14 ppm. HRMS (ESI) m/z: [M
+ H]+ calcd for C28H43N2O7S, 551.2785; found 551.2786.
tert-Butyl ((2S,3R)-4-((4-((R)-1,2-Dihydroxyethyl)-N-(2-
ethylbutyl)phenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)-
carbamate (20c). The same procedure was used as described above
for compound 20a. Compound 19c (1.30 g, 2.45 mmol) was treated
with AD-mix-ß (3.50 g), and the reaction was quenched with sodium
sulfite (4.00 g) to give compound 20c as a white solid (1.02 g, 74%).
1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.0 Hz, 2 H), 7.53 (d, J =
8.0 Hz, 2 H), 7.31−7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 4.90 (d, J =
7.5 Hz, 1 H), 4.58 (d, J = 7.0 Hz, 1 H), 3.92 (s, 1 H), 3.82 (d, J = 11.0
Hz, 1 H), 3.77−3.71 (m, 2 H), 3.64 (t, J = 10.0 Hz, 1 H), 3.13−2.98
(m, 4 H), 2.92−2.81 (m, 3 H), 2.15 (br s, 1 H), 1.48−1.38 (m, 2 H),
1.36−1.23 (m, 3 H), 1.34 (s, 9 H, overlapping), 0.83−0.79 (m, 6 H)
ppm. 13C NMR (125 MHz, CDCl3) δ 156.23, 146.25, 137.75, 137.52,
129.61, 128.59, 127.59, 126.98, 126.58, 79.98, 73.95, 72.88, 67.80,
54.74, 54.61, 53.47, 38.95, 35.77, 28.34, 23.06, 22.81, 10.61, 10.41
ppm. HRMS (ESI) m/z: [M + H]+ calcd for C29H45N2O7S, 565.2942;
found 565.2939.
tert -Butyl ( (2S,3R)-4-( (4- ( (S )-1 ,2-Dihydroxyethyl ) -N-
isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)-
carbamate (21a). The same procedure was used as described above
for compound 20a. Compound 19a (0.65 g, 1.30 mmol) was treated
with AD-mix-α (2.10 g), and the reaction was quenched with sodium
sulfite (2.5 g) to give compound 21a as a white solid (0.33 g, 47%).
1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.5 Hz, 2 H), 7.52 (d, J =
8.5 Hz, 2 H), 7.31−7.28 (m, 2 H), 7.25−7.21 (m, 3 H), 4.91−4.88
(m, 1 H), 4.63 (d, J = 7.5 Hz, 1 H), 3.92 (s, 1 H), 3.83−3.70 (m, 3
H), 3.66−3.61 (m, 1 H), 3.14−3.06 (m, 2 H), 3.02−2.81 (m, 5 H),
2.13 (t, J = 5.4 Hz, 1 H), 1.89−1.81 (m, 1 H), 1.34 (s, 9 H), 0.90 (d, J
= 6.5 Hz, 3 H), 0.86 (d, J = 6.5 Hz, 3 H) ppm. 13C NMR (125 MHz,
CDCl3) δ 156.29, 145.86, 138.01, 137.90, 129.69, 128.65, 127.72,
126.97, 126.62, 79.96, 74.02, 72.90, 67.90, 58.75, 54.88, 53.80, 35.61,
28.39, 27.32, 20.25, 20.00 ppm. HRMS (ESI) m/z: [M + H]+ calcd
for C27H41N2O7S, 537.2629; found 537.2631.
tert-Butyl ((2S,3R)-4-((4-((S)-1,2-Dihydroxyethyl)-N-((S)-2-
methylbutyl)phenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)-
carbamate (21b). The same procedure was used as described above
for compound 20a. Compound 19b (1.00 g, 1.94 mmol) was treated
with AD-mix-α (2.80 g), and the reaction was quenched with solid
sodium sulfite (3.00 g) to give compound 21b as a white solid (0.92 g,
86%). 1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.5 Hz, 2 H), 7.52
(d, J = 8.5 Hz, 2 H), 7.31−7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 4.91−
4.88 (m, 1 H), 4.62 (d, J = 7.1 Hz, 1 H), 3.87 (br s, 1 H), 3.83−3.71
(m, 3 H), 3.66−3.61 (m, 1 H), 3.13−2.87 (m, 5 H), 2.85−2.80 (m, 2
H), 2.16 (t, J = 5.5 Hz, 1 H), 1.65−1.58 (m, 1 H), 1.51−1.43 (m, 1
H), 1.35 (s, 9 H), 1.10−1.02 (m, 1 H), 0.86−0.83 (m, 6 H) ppm. 13C
NMR (125 MHz, CDCl3) δ 156.22, 145.86, 137.92, 137.80, 129.70,
128.66, 127.73, 126.96, 126.64, 79.96, 74.02, 72.77, 67.90, 57.32,
54.78, 53.71, 35.63, 33.49, 28.40, 26.56, 17.01, 11.18 ppm. HRMS




carbamate (21c). The same procedure was used as described above
for compound 20a. Compound 19c (1.50 g, 2.45 mmol) was treated
with AD-mix-α (3.80 g), and the reaction was quenched with sodium
sulfite (4.00 g) to give compound 21c as a white solid (0.95 g, 60%).
1H NMR (500 MHz, CDCl3) δ 7.76 (d, J = 8.5 Hz, 2 H), 7.53 (d, J =
8.5 Hz, 2 H), 7.31−7.28 (m, 2 H), 7.25−7.20 (m, 3 H), 4.92−4.89
(m, 1 H), 4.58 (d, J = 7.0 Hz, 1 H), 3.93 (s, 1 H), 3.84−3.80 (m, 1
H), 3.77−3.71 (m, 2 H), 3.66−3.62 (m, 1 H), 3.13−2.98 (m, 4 H),
2.93−2.77 (m, 3 H), 2.16−2.08 (m, 1 H), 1.48−1.37 (m, 2 H), 1.36−
1.20 (m, 3 H), 1.34 (s, 9 H, overlapping), 0.83−0.79 (m, 6 H) ppm.
13C NMR (125 MHz, CDCl3) δ 156.23, 146.13, 137.77, 137.61,
129.65, 128.63, 127.65, 126.99, 126.62, 79.99, 73.98, 72.94, 67.85,
54.72, 53.57, 39.01, 35.79, 28.37, 23.11, 22.83, 10.65, 10.42 ppm.




phenylbutan-2-yl)carbamate (22). A solution of compound 20a
(0.78 g, 1.45 mmol) in anhydrous dichloromethane (5 mL) was
treated with a solution of 4 N HCl in 1,4-dioxane (10 mL). After the
reaction mixture was stirred at room temperature for 2.5 h, solvents
were evaporated under reduced pressure, and the residue was
triturated with diethyl ether and dried under high vacuum. A solution
of the deprotected amine salt in anhydrous acetonitrile (15 mL) was
cooled to 0 °C and treated with diisopropylethylamine (0.75 g, 5.813
mmol) followed by bis-THF activated carbonate 11 (0.39 g, 1.45
mmol). The resulting reaction mixture was stirred at room
temperature for 24 h. Solvents were evaporated under reduced
pressure, and the residue was purified by automated flash
chromatography using a silica gel column (RediSep Gold, 40 g,
gradient elution with 0−20% methanol/dichloromethane) to give
compound 22 (0.28 g, 33%) as a white solid. 1H NMR (500 MHz,
CDCl3) δ 7.76 (d, J = 8.3 Hz, 2 H), 7.55 (d, J = 8.2 Hz, 2 H), 7.30−
7.27 (m, 2 H), 7.22−7.20 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1 H), 4.99 (q,
J = 7.0 Hz, 1 H), 4.93−4.89 (m, 2 H), 3.94 (dd, J = 9.6, 6.3 Hz, 1 H),
3.89−3.81 (m, 4 H), 3.69−3.62 (m, 3 H), 3.56 (br s, 1 H), 3.16 (dd, J
= 15.5, 8.5 Hz, 1 H), 3.08 (dd, J = 13.5, 3.0 Hz, 1 H), 3.02−2.97 (m,
3 H), 2.91−2.83 (m, 2 H), 2.79 (dd, J = 13.5, 9.0 Hz, 1 H), 1.88−
1.81 (m, 1 H), 1.68−1.60 (m, 1 H), 1.49−1.46 (m, 1 H), 0.94 (d, J =
6.6 Hz, 3 H), 0.89 (d, J = 6.6 Hz, 3 H) ppm. 13C NMR (100 MHz,
CDCl3) δ 155.61, 146.12, 137.59, 129.48, 128.74, 127.68, 127.08,
126.79, 109.44, 73.93, 73.62, 72.89, 71.04, 69.78, 67.83, 59.04, 55.24,
53.92, 45.45, 35.80, 27.46, 26.00, 20.28, 20.00 ppm. HRMS (ESI) m/
z: [M + H]+ calcd for C29H41N2O9S, 593.2527; found 593.2528. Anal.
HPLC: tR 9.69 min, purity 99%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-((4-((S)-
1,2-Dihydroxyethyl)-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-
phenylbutan-2-yl)carbamate (23). The same procedure was used as
described above for compound 22. Compound 21a (0.35 g, 0.652
mmol) was treated with 4 N HCl in 1,4-dioxane (5 mL), and the
resulting amine salt was treated with diisopropylethylamine (0.34 g,
2.61 mmol) and bis-THF activated carbonate 11 (0.18 g, 0.652
mmol) to give compound 23 (0.34 g, 77%) as a white solid. 1H NMR
(500 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2 H), 7.55 (d, J = 8.2 Hz, 2
H), 7.30−7.27 (m, 2 H), 7.23−7.20 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1
H), 4.99 (q, J = 6.0 Hz, 1 H), 4.92−4.87 (m, 2 H), 3.93 (dd, J = 9.6,
6.2 Hz, 1 H), 3.88−3.81 (m, 4 H), 3.70−3.62 (m, 3 H), 3.54 (br s, 1
H), 3.17−3.07 (m, 2 H), 3.02−2.97 (m, 3 H), 2.92−2.74 (m, 3 H),
2.15 (br s, 1 H), 1.88−1.82 (m, 1 H), 1.69−1.60 (m, 1 H), 1.52−1.48
(m, 1 H), 0.94 (d, J = 6.7 Hz, 3 H), 0.90 (d, J = 6.6 Hz, 3 H) ppm.
13C NMR (100 MHz, CDCl3) δ 155.60, 146.15, 137.56, 129.48,
128.75, 127.70, 127.5, 126.80, 109.46, 73.91, 73.63, 72.89, 71.10,
69.79, 67.85, 59.12, 55.22, 53.99, 45.43, 35.87, 27.47, 26.02, 20.28,
20.00 ppm. HRMS (ESI) m/z: [M + H]+ calcd for C29H41N2O9S,
593.2527; found 593.2530. Anal. HPLC: tR 9.85 min, purity 98%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-((4-((R)-
1,2-Dihydroxyethyl)-N-((S)-2-methylbutyl)phenyl)sulfonamido)-3-
hydroxy-1-phenylbutan-2-yl)carbamate (24). The same procedure
was used as described above for compound 22. Compound 20b (0.52
g, 0.944 mmol) was treated with 4 N HCl in 1,4-dioxane (8 mL), and
the resulting amine salt was treated with disopropylethylamine (0.49
g, 3.776 mmol) and bis-THF activated carbonate 11 (0.26 g, 0.944
mmol) to give compound 24 (0.40 g, 70%) as a white solid. 1H NMR
(500 MHz, CDCl3) δ 7.76 (d, J = 8.1 Hz, 2 H), 7.55 (d, J = 8.1 Hz, 2
H), 7.30−7.27 (m, 2 H), 7.22−7.20 (m, 3 H), 5.64 (d, J = 5.1 Hz, 1
H), 5.01 (q, J = 6.5 Hz, 1 H), 4.91−4.87 (m, 2 H), 3.94 (dd, J = 9.5,
6.5 Hz, 1 H), 3.86−3.80 (m, 4 H), 3.70−3.62 (m, 3 H), 3.52 (br s, 1
H), 3.17−2.97 (m, 4 H), 3.91−2.97 (m, 4 H), 2.16 (br s, 1 H), 1.69−
1.47 (m, 4 H) 1.14−1.05 (m, 1 H), 0.88−0.86 (m, 6 H) ppm. 13C
NMR (100 MHz, CDCl3) δ 155.63, 146.40, 137.66, 137.34, 129.44,
128.65, 127.60, 127.05, 126.70, 109.43, 73.90, 73.51, 72.77, 71.13,
69.77, 67.73, 57.32, 55.28, 53.59, 45.53, 35.81, 33.45, 26.61, 25.97,
17.02, 11.23 ppm. HRMS (ESI) m/z: [M + H]+ calcd for




hydroxy-1-phenylbutan-2-yl)carbamate (25). The same procedure
was used as described above for compound 22. Compound 21b (0.45
g, 0.817 mmol) was treated with 4 N HCl in 1,4-dioxane (8 mL), and
the resulting amine salt was treated with diisopropylethylamine (0.42
g, 3.27 mmol) and bis-THF activated carbonate 11 (0.22 g, 0.817
mmol) to give compound 25 (0.39 g, 79%) as a white solid. 1H NMR
(400 MHz, CDCl3) δ 7.76 (d, J = 8.3 Hz, 2 H), 7.55 (d, J = 8.3 Hz, 2
H), 7.30−7.27 (m, 2 H), 7.23−7.20 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1
H), 4.99 (q, J = 6.0 Hz 1 H), 4.91−4.87 (m, 2 H), 3.93 (dd, J = 9.5,
6.0 Hz, 1 H), 3.87−3.81 (m, 4 H), 3.71−3.62 (m, 3 H), 3.50 (br s, 1
H), 3.15−2.97 (m, 5 H), 2.92−2.78 (m, 3 H), 1.70−1.45 (m, 4 H),
1.14−1.05 (m, 1 H), 0.88−0.85 (m, 6 H) ppm. 13C NMR (100 MHz,
CDCl3) δ 155.63, 146.44, 137.66, 137.28, 129.45, 128.65, 127.62,
127.03, 126.70, 109.44, 73.88, 73.51, 72.78, 71.19, 69.78, 67.74, 57.38,
55.28, 53.63, 45.52, 35.86, 33.46, 26.63, 25.98, 17.02, 11.23 ppm.
HRMS (ESI) m/z: [M + H]+ calcd for C30H43N2O9S, 607.2684;
found 607.2687. Anal. HPLC: tR 10.39 min, purity 97%.
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-((4-((R)-
1,2-Dihydroxyethyl)-N-(2-ethylbutyl)phenyl)sulfonamido)-3-hy-
droxy-1-phenylbutan-2-yl)carbamate (26). The same procedure
was used as described above for compound 22. Compound 20c (0.51
g, 0.903 mmol) was treated with 4 N HCl in 1,4-dioxane (8 mL), and
the resulting amine salt was treated with diisopropylethylamine (0.47
g, 3.61 mmol) and bis-THF activated carbonate 11 (0.24 g, 0.903
mmol) to give compound 26 (0.31 g, 64%) as a white solid. 1H NMR
(500 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2 H), 7.55 (d, J = 8.2 Hz, 2
H), 7.30−7.27 (m, 2 H), 7.22−7.20 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1
H), 5.00 (q, J = 6.5 Hz, 1 H), 4.90 (dd, J = 7.8, 3.4 Hz, 1 H), 4.86 (d,
J = 9.0 Hz, 1 H), 3.93 (dd, J = 9.7, 6.3 Hz, 1 H), 3.87−3.78 (m, 4 H),
3.69−3.62 (m, 4 H), 3.16−3.04 (m, 3 H), 2.98 (d, J = 15.0 Hz, 1 H),
2.91−2.87 (m, 2 H), 2.80 (dd, J = 14.1, 9.3 Hz, 1 H), 1.68−1.60 (m,
1 H), 1.50−1.39 (m, 3 H), 1.35−1.25 (m, 3 H), 0.85−0.81 (m, 6 H)
ppm. 13C NMR (100 MHz, CDCl3) δ 155.62, 146.38, 137.64, 137.22,
129.45, 128.67, 127.65, 127.08, 126.72, 109.43, 73.92, 73.54, 73.11,
71.05, 69.77, 67.76, 55.23, 54.85, 53.68, 45.51, 39.05, 35.91, 25.96,
23.06, 22.84, 10.65, 10.45 ppm. HRMS (ESI) m/z: [M + H]+ calcd




droxy-1-phenylbutan-2-yl)carbamate (27). The same procedure
was used as described above for compound 22. Compound 21c (0.50
g, 0.885 mmol) was treated with 4 N HCl in dioxane (10 mL), and
the resulting amine salt was treated with diisopropylethylamine (0.46
g, 3.54 mmol) and bis-THF activated carbonate 11 (0.24 g, 0.885
mmol) to give compound 27 (0.31 g, 57%) as a white solid. 1H NMR
(400 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2 H), 7.56 (d, J = 8.2 Hz, 2
H), 7.30−7.27 (m, 2 H), 7.22−7.20 (m, 3 H), 5.64 (d, J = 5.2 Hz, 1
H), 5.01−4.99 (q, J = 6.0 Hz, 1 H), 4.91 (d, J = 7.0 Hz, 1 H), 4.83 (d,
J = 9.0 Hz, 1 H), 3.92 (dd, J = 9.6, 6.2 Hz, 1 H), 3.88−3.80 (m, 4 H),
3.70−3.60 (m, 4 H), 3.15−3.05 (m, 3 H), 2.99 (d, J = 15.0, 2.0 Hz, 1
H), 2.92−2.89 (m, 2 H), 2.80 (dd, J = 14.1, 9.2 Hz, 1 H), 2.12 (br s, 1
H), 1.69−1.61 (m, 1 H), 1.51−1.39 (m, 3 H), 1.35−1.28 (m, 3 H),
0.85−0.81 (m, 6 H) ppm. 13C NMR (100 MHz, CDCl3) δ 155.59,
146.18, 137.52, 137.28, 129.49, 128.75, 127.74, 127.06, 126.80,
109.45, 73.92, 73.63, 73.13, 71.05, 69.78, 67.84, 55.12, 53.95, 45.44,
39.24, 36.00, 26.00, 23.14, 22.87, 10.73, 10.45 ppm. HRMS (ESI) m/
z: [M + H]+ calcd for C31H45N2O9S, 621.2840; found 621.2847. Anal.
HPLC: tR 11.15 min, purity 99%.
Antiviral Assays. 293T and TZM-BL36 cells (NIH AIDS
Research and Reference Reagent Program) were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
calf serum in the presence of penicillin and streptomycin at 37 °C
with 5% CO2. To determine the concentration of drugs achieving 50%
inhibition of infection compared with the drug-free control, 4.5 × 106
293T cells were seeded onto a 10-cm plate 24 h before transfection.
Cells were transfected with 8 μg of either the wild-type plasmid,
infectious molecular clone pNL-CH derived from the pNL4-3 clone
of HIV-1, or each PI-resistant HIV-1 variant34 using FuGENE 6
transfection reagent (Roche). The culture supernatant of 293T cells
transfected with wild-type or PI-resistant HIV-1 variant was removed
18 h after transfection, and the cells were washed with 1 × PBS. The
293T cells were collected and transferred to wells of a 24-well plate.
Briefly, each drug was serially diluted in the culture medium, and the
dilutions were added to the wells of a 24-well plate. The 293T cells
(0.5 × 106 per well) collected from the transfection were added to
wells containing various concentrations of drug. The culture
supernatant containing virus particles was harvested 18 h after the
293T cells were reseeded in the presence of drug. This supernatant
was filtered through a 0.45-μm-pore-size membrane (Millipore) to
remove cell debris and then used to infect 2 × 104 TZM-BL cells in a
96-well plate following a procedure previously described.37 The
culture supernatant was removed from each well 48 h postinfection,
and the cells were washed with 1 × PBS. For the luciferase assay,
infected TZM-BL cells were lysed in 1 × reporter lysis buffer
(Promega) and the cells were kept at −80 °C. After one freeze−thaw
cycle, the cell lysates were transferred into a 96-well assay plate
(Costar), and luciferase activity was measured using a luminometer
(Promega). The culture supernatant harvested from 293T cells
reseeded in the absence of drugs was used as a drug-free control. EC50
was determined based on a dose−response curve generated using
GraphPad Prism (version 7.0).
Protease Gene Construction. Protease gene construction was
carried out as previously described.38,39 The NL4-3 strain has four
naturally occurring polymorphisms in the protease relative to the SF2
strain.40 In short, the protease variant genes (I84V, I50V/A71V) were
constructed using QuikChange site-directed mutagenesis (Genewiz)
onto NL4-3 wild-type protease on a pET11a plasmid with codon
optimization for protein expression in Escherichia coli. A Q7K
mutation was included to prevent autoproteolysis.41
Protein Expression and Purification. The expression, isolation,
and purification of WT and mutant HIV-1 proteases used for the
kinetic assays and crystallization were carried out as previously
described.38,39 Briefly, the gene encoding the HIV protease was
subcloned into the heat-inducible pXC35 expression vector (ATCC)
and transformed into E. coli TAP-106 cells. Cells grown in 6 L of
Terrific Broth were lysed with a cell disruptor, and the protein was
purified from inclusion bodies.42 The inclusion body centrifugation
pellet was dissolved in 50% acetic acid followed by another round of
centrifugation to remove impurities. Size exclusion chromatography
was used to separate high molecular weight proteins from the desired
protease. This was carried out on a 2.1 L Sephadex G-75 superfine
column (Millipore Sigma) equilibrated with 50% acetic acid. The
cleanest fractions of HIV protease were refolded into a 10-fold
dilution of 0.05 M sodium acetate at pH 5.5, 5% ethylene glycol, 10%
glycerol, and 5 mM DTT. Folded protein was concentrated down to
0.7−2 mg/mL and stored. This stored protease was used in Km and Ki
assays. For crystallography, a final purification was performed with a
Pharmacia Superdex 75 FPLC column equilibrated with 0.05 M
sodium acetate at pH 5.5, 5% ethylene glycol, 10% glycerol, and 5
mM DTT. Protease fractions purified from the size exclusion column
were concentrated to 1−2 mg/mL using an Amicon Ultra-15 10-kDa
device (Millipore) for crystallization.
Enzyme Inhibition Assays. The Km and Ki assays were carried
out as previously described.31,43 In the Km assay, a 10-amino acid
substrate containing the natural MA/CA cleavage site with an
EDANS/DABCYL FRET pair was dissolved in 8% DMSO at 40 nM
and 6% DMSO at 30 nM. The 30 nM of substrate was 4/5th serially
diluted from 30 nM to 6 nM, including a 0 nM control. HIV protease
was diluted to 120 nM and, using a PerkinElmer Envision plate
reader, 5 μL was added to the 96-well plate to obtain a final
concentration of 10 nM. The fluorescence was observed with an
excitation at 340 nm and emission at 492 nm and monitored for 200
counts, for approximately 23 min. FRET inner filter effect correction
was applied as previously described.44 Corrected data were analyzed
with Prism7.
To determine the enzyme inhibition constant (Ki), in a 96-well
plate, each inhibitor was 2/3 serially diluted from 3 nM to 52 pM,
including a 0 pM control, and incubated with 0.35 nM protein for 1 h.
A 10-amino acid substrate containing an optimized protease cleavage
site with an EDANS/DABCYL FRET pair was dissolved in 4%
DMSO at 120 μM. Using the Envision plate reader, 5 μL of the 120
μM substrate was added to the 96-well plate to a final concentration
of 10 μM. The fluorescence was observed with an excitation at 340
nm and emission at 492 nm and monitored for 200 counts, for
approximately 60 min. Data was analyzed with Prism7.
Protein Crystallization. The condition reliably producing
cocrystals of NL4-3 WT protease bound to PIs was discovered and
optimized as previously described.45 Briefly, all cocrystals were grown
at room temperature by a hanging drop vapor diffusion method in 24-
well VDX hanging-drop trays (Hampton Research) with a protease
concentration of 1.0−1.7 mg/mL with 3-fold molar excess of
inhibitors. Crystallization drops of 1 μL of protein-inhibitor solution
and 2 μL of reservoir solution consisted of 22−26% (w/v)
ammonium sulfate with 0.1 M bis-Tris-methane buffer at pH 5.5.
Drops were microseeded with a cat whisker. Diffraction quality
crystals were obtained within 1 week. As data were collected at 100 K,
cryogenic conditions contained the precipitant solution supplemented
with 25% glycerol.
X-ray Data Collection and Structure Solution. X-ray
diffraction data were collected and solved as previously de-
scribed.39,45,46 Diffraction quality crystals were flash frozen under a
cryostream when mounting the crystal at our in-house Rigaku_Sa-
turn944 X-ray system. The cocrystal diffraction intensities were
indexed, integrated, and scaled using HKL3000.47 Structures were
solved using molecular replacement with PHASER.48 Model building
and refinement were performed using Coot49 and Phenix.50 Ligands
were designed in Maestro, and the output sdf files were used in the
Phenix program eLBOW51 to generate cif files containing atomic
positions and constraints necessary for ligand refinement. Iterative
rounds of crystallographic refinement were carried out until
convergence was achieved. To limit bias throughout the refinement
process, five percent of the data were reserved for the free R-value
calculation.52 MolProbity53 was applied to evaluate the final structures
before deposition in the PDB. Structure analysis, superposition, and
figure generation was done using PyMOL.54 X-ray data collection and
crystallographic refinement statistics are presented in the Supporting
Information (Table S2).
Molecular Modeling. Molecular modeling was carried out using
MacroModel (Schrödinger, LLC, New York, NY).55 Briefly, inhibitors
were modeled into the active site of wild-type HIV-1 protease using
the protease-3 and protease-4 cocomplex structures (PDB codes:
3O9B and 3O9G).23 Structures were prepared using the Protein
Preparation tool in Maestro 11 (Schrödinger, LLC, New York, NY).55
2D chemical structures were modified with the appropriate changes
using the Build tool in Maestro. Once modeled, molecular energy
minimizations were performed for each inhibitor−protease complex
using the PRCG method with 2500 maximum iterations and 0.05
gradient convergence threshold. PDB files of modeled complexes were
generated in Maestro for structural analysis.
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